Yan Wei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yan Wei has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Jiacan Su
Department of Orthopedics Xinhua Hospital Shanghai Jiao Tong University School of Medicine Shanghai China
7 shared publications - Can Xu
Department of Gastroenterology, Changhai Hospital, Shanghai 200433, China
5 shared publications Dongyang Zhou
Shanghai University
5 shared publicationsJiajing Lv
Institute of translational medicine, Shanghai University, Shanghai, 200444, China
5 shared publicationsHongbo Li
4 shared publicationsJing Yan
4 shared publications
Latest Publications
- Open Access
- 5 August 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (8) , 964
Dual Drug-Loaded Enzyme-Responsive Liposomes Exert Specific Modulation on Liver Cancer Cells and Tumor-Associated Macrophages In Vitro
Background: Hepatocellular carcinoma (HCC) is a highly lethal malignancy and remains a major contributor to global cancer mortality. In situ vaccination (ISV) holds great potential for HCC therapy. Still, its efficacy is severely limited by intrinsic antigen scarcity and the tumor-associated macrophage (TAM)-mediated inhibition of dendritic cell (DC) maturation and T cell activation. In particular, the M2 TAM-HCC cell crosstalk may further aggravate ISV suppression. Moreover, as an internal organ tumor, HCC requires systemic administration of ISV agents, which often cause severe off-target toxicity. Methods: To address these challenges, we developed secretory phospholipase A2 (sPLA2)-responsive liposomes co-loaded with the TLR7/8 agonist R848 and the ICD inducer doxorubicin (DOX) via a sequential remote loading method, termed sP-Lips@DR. Results: Incorporation of cholesterol (CHOL) significantly improved DOX encapsulation, and the sequential loading method enabled efficient co-encapsulation of both R848 and DOX. sP-Lips@DR responds to an sPLA2-overexpressed, mildly acidic microenvironment in HCC, enabling selective drug release. In addition, sP-Lips@DR exhibited sPLA2-responsive cytotoxicity toward H22 cells and macrophage phenotypic shift. Furthermore, sP-Lips@DR could disrupt the crosstalk between M2-like macrophages and H22 cells in an sPLA2-responsive manner. Conclusions: Overall, the preparation and in vitro evaluation of sP-Lips@DR demonstrate their potential to enhance ISV efficacy in HCC, providing a solid foundation for future in vivo investigations.
- 5 August 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (8) , 964
Open AccessDual Drug-Loaded Enzyme-Responsive Liposomes Exert Specific Modulation on Liver Cancer Cells and Tumor-Associated Macrophages In Vitro
Background: Hepatocellular carcinoma (HCC) is a highly lethal malignancy and remains a major contributor to global cancer mortality. In situ vaccination (ISV) holds great potential for HCC therapy. Still, its efficacy is severely limited by intrinsic antigen scarcity and the tumor-associated macrophage (TAM)-mediated inhibition of dendritic cell (DC) maturation and T cell activation. In particular, the M2 TAM-HCC cell crosstalk may further aggravate ISV suppression. Moreover, as an internal organ tumor, HCC requires systemic administration of ISV agents, which often cause severe off-target toxicity. Methods: To address these challenges, we developed secretory phospholipase A2 (sPLA2)-responsive liposomes co-loaded with the TLR7/8 agonist R848 and the ICD inducer doxorubicin (DOX) via a sequential remote loading method, termed sP-Lips@DR. Results: Incorporation of cholesterol (CHOL) significantly improved DOX encapsulation, and the sequential loading method enabled efficient co-encapsulation of both R848 and DOX. sP-Lips@DR responds to an sPLA2-overexpressed, mildly acidic microenvironment in HCC, enabling selective drug release. In addition, sP-Lips@DR exhibited sPLA2-responsive cytotoxicity toward H22 cells and macrophage phenotypic shift. Furthermore, sP-Lips@DR could disrupt the crosstalk between M2-like macrophages and H22 cells in an sPLA2-responsive manner. Conclusions: Overall, the preparation and in vitro evaluation of sP-Lips@DR demonstrate their potential to enhance ISV efficacy in HCC, providing a solid foundation for future in vivo investigations.
- Open Access
- 22 July 2026
- Published by SAGE Publications in Natural Product Communications
- Vol. 21 (7)
Chemical Ingredients and Antitumor Application of Dragon’s Blood
Dragon’s blood is a deep red resin derived from the injured trunk or branch of Dracaena plants. Dragon’s blood is well known for its ability to improve blood circulation and disperse blood stasis in traditional medicine. Thus, it is extensively used for treating diarrhea, wounds, piles, fractures, and stomach and intestinal ulcers. Modern pharmacological studies have revealed that Dragon’s blood can inhibit tumor growth through various mechanisms. Besides the extracts, some ingredients with antitumor activity have been successfully isolated from Dragon’s blood, such as loureirin, liquiritigenin, pterostilbene, resveratrol, and β-sitosterol. Herein, we elaborated on the antitumor activity and action mechanisms of certain extracts and active ingredients from Dragon’s blood. Furthermore, given the excellent vascular modulation activity of Dragon’s blood, we proposed employing its certain extracts or active ingredients as tumor vascular modulation agents for enhanced delivery and efficacy of chemotherapeutic agents or nanomedicine. We strongly believe that this review will offer an overview and a prospect of employing Dragon’s blood for tumor treatment.
- 22 July 2026
- Published by SAGE Publications in Natural Product Communications
- Vol. 21 (7)
Open AccessChemical Ingredients and Antitumor Application of Dragon’s Blood
Dragon’s blood is a deep red resin derived from the injured trunk or branch of Dracaena plants. Dragon’s blood is well known for its ability to improve blood circulation and disperse blood stasis in traditional medicine. Thus, it is extensively used for treating diarrhea, wounds, piles, fractures, and stomach and intestinal ulcers. Modern pharmacological studies have revealed that Dragon’s blood can inhibit tumor growth through various mechanisms. Besides the extracts, some ingredients with antitumor activity have been successfully isolated from Dragon’s blood, such as loureirin, liquiritigenin, pterostilbene, resveratrol, and β-sitosterol. Herein, we elaborated on the antitumor activity and action mechanisms of certain extracts and active ingredients from Dragon’s blood. Furthermore, given the excellent vascular modulation activity of Dragon’s blood, we proposed employing its certain extracts or active ingredients as tumor vascular modulation agents for enhanced delivery and efficacy of chemotherapeutic agents or nanomedicine. We strongly believe that this review will offer an overview and a prospect of employing Dragon’s blood for tumor treatment.
- Open Access
An Ultrasound-Responsive Bio-Adhesive Piezoelectric Hydrogel for Osteoarthritis Cartilage
Osteoarthritis (OA) is a degenerative joint disease characterized by progressive loss of articular cartilage and an associated decline in its intrinsic mechanoelectrical signaling. Current osteoarthritis treatments relieve symptoms but fail to prevent cartilage degeneration or restore its native biophysical microenvironment. Here, we present an ultrasound-activated, mussel-inspired bio-adhesive hydrogel that addresses these challenges by recreating the cartilage’s piezoelectric cues in situ while achieving stable intra-articular retention under synovial conditions. The hydrogel, denoted SFHD-BT@PDA, consists of a silk fibroin (SF) matrix integrated with dopamine-functionalized hyaluronic acid (HADA) and embedded barium titanate nanoparticles coated with polydopamine (BT@PDA). This multi-level design imparts strong interfacial adhesion to wet cartilage (via catechol-mediated bonding to collagen) and piezoelectric sensitivity to external ultrasound. Under ultrasound stimulation, SFHD-BT@PDA generates localized electrical microcurrents that recruit endogenous MSCs via electrotaxis and subsequently promote their chondrogenic differentiation. In vitro, ultrasound-triggered electrical cues upregulated chondrogenic markers (SOX9, collagen II, aggrecan) in MSCs and activated TGF-β signaling, demonstrating restoration of the pro-anabolic bioelectric microenvironment. In a murine DMM model, the adhesive hydrogel exhibited prolonged retention on cartilage surfaces and, with ultrasound, induced robust cartilage regeneration and OA reversal. Treated joints showed preserved proteoglycan and Type II collagen content, inhibited osteophyte formation, and protection of subchondral bone microarchitecture. In summary, this mussel-inspired piezoelectric hydrogel provides an electromechanical stimulation platform that effectively couples physical cues with bio-adhesion to regenerate cartilage.
Open AccessAn Ultrasound-Responsive Bio-Adhesive Piezoelectric Hydrogel for Osteoarthritis Cartilage
Osteoarthritis (OA) is a degenerative joint disease characterized by progressive loss of articular cartilage and an associated decline in its intrinsic mechanoelectrical signaling. Current osteoarthritis treatments relieve symptoms but fail to prevent cartilage degeneration or restore its native biophysical microenvironment. Here, we present an ultrasound-activated, mussel-inspired bio-adhesive hydrogel that addresses these challenges by recreating the cartilage’s piezoelectric cues in situ while achieving stable intra-articular retention under synovial conditions. The hydrogel, denoted SFHD-BT@PDA, consists of a silk fibroin (SF) matrix integrated with dopamine-functionalized hyaluronic acid (HADA) and embedded barium titanate nanoparticles coated with polydopamine (BT@PDA). This multi-level design imparts strong interfacial adhesion to wet cartilage (via catechol-mediated bonding to collagen) and piezoelectric sensitivity to external ultrasound. Under ultrasound stimulation, SFHD-BT@PDA generates localized electrical microcurrents that recruit endogenous MSCs via electrotaxis and subsequently promote their chondrogenic differentiation. In vitro, ultrasound-triggered electrical cues upregulated chondrogenic markers (SOX9, collagen II, aggrecan) in MSCs and activated TGF-β signaling, demonstrating restoration of the pro-anabolic bioelectric microenvironment. In a murine DMM model, the adhesive hydrogel exhibited prolonged retention on cartilage surfaces and, with ultrasound, induced robust cartilage regeneration and OA reversal. Treated joints showed preserved proteoglycan and Type II collagen content, inhibited osteophyte formation, and protection of subchondral bone microarchitecture. In summary, this mussel-inspired piezoelectric hydrogel provides an electromechanical stimulation platform that effectively couples physical cues with bio-adhesion to regenerate cartilage.
- 29 December 2025
- Published by Springer Nature in Nature Nanotechnology
- Vol. 21 (2) , 300-310
Viral glycoprotein-mimicking peptide-functionalized micelles promote drug delivery to diseased chondrocytes for osteoarthritis alleviation
Osteoarthritis (OA) affects a large population worldwide, causing chronic pain, functional decline, and increased personal and societal medical costs. A major challenge in developing disease-modifying OA drugs (DMOADs) is the inefficient delivery to diseased chondrocytes. Here we synthesize a viral glycoprotein-mimicking peptide (CMP) containing a type II collagen-adhesive motif and a matrix metalloproteinase-13-activated cell-penetrating peptide sequence. The CMP peptide was conjugated to small-sized micelles loaded with the model drug IOX4, enabling the micelles to adhere to cartilage and chondrocyte surfaces through collagen binding and achieve proteinase-induced selective uptake by diseased chondrocytes. In an OA mouse model, our micelles demonstrated prolonged joint retention and exhibited a higher uptake by diseased chondrocytes compared with unmodified micelles and normal chondrocytes, respectively. In both OA mice and a clinically relevant OA sheep model, our system maintained metabolic homeostasis in cartilage, attenuating OA pathological changes and improving symptoms without causing additional toxicity. These findings suggest that our nanoformulation is a promising DMOAD candidate and provides an efficient delivery strategy for other potential DMOADs targeting intracellular sites of diseased chondrocytes.
- 29 December 2025
- Published by Springer Nature in Nature Nanotechnology
- Vol. 21 (2) , 300-310
Viral glycoprotein-mimicking peptide-functionalized micelles promote drug delivery to diseased chondrocytes for osteoarthritis alleviation
Osteoarthritis (OA) affects a large population worldwide, causing chronic pain, functional decline, and increased personal and societal medical costs. A major challenge in developing disease-modifying OA drugs (DMOADs) is the inefficient delivery to diseased chondrocytes. Here we synthesize a viral glycoprotein-mimicking peptide (CMP) containing a type II collagen-adhesive motif and a matrix metalloproteinase-13-activated cell-penetrating peptide sequence. The CMP peptide was conjugated to small-sized micelles loaded with the model drug IOX4, enabling the micelles to adhere to cartilage and chondrocyte surfaces through collagen binding and achieve proteinase-induced selective uptake by diseased chondrocytes. In an OA mouse model, our micelles demonstrated prolonged joint retention and exhibited a higher uptake by diseased chondrocytes compared with unmodified micelles and normal chondrocytes, respectively. In both OA mice and a clinically relevant OA sheep model, our system maintained metabolic homeostasis in cartilage, attenuating OA pathological changes and improving symptoms without causing additional toxicity. These findings suggest that our nanoformulation is a promising DMOAD candidate and provides an efficient delivery strategy for other potential DMOADs targeting intracellular sites of diseased chondrocytes.
- Open Access
- 6 November 2024
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 22 (1) , 1-21
Organoids and organoid extracellular vesicles-based disease treatment strategies
Organoids are “mini-organs” that self-organize and differentiate from stem cells under in vitro 3D culture conditions, mimicking the spatial structure and function of tissues in vivo. Extracellular vesicles (EVs) are nanoscale phospholipid bilayer vesicles secreted by living cells, rich in bioactive molecules, with excellent biocompatibility and low immunogenicity. Compared to EVs, organoid-derived EVs (OEVs) exhibit higher yield and enhanced biological functions. Organoids possess stem cell characteristics, and OEVs are capable of delivering active substances, making both highly promising for medical applications. In this review, we provide an overview of the fundamental biological principles of organoids and OEVs, and discuss their current applications in disease treatment. We then focus on the differences between OEVs and traditional EVs. Subsequently, we present methods for the engineering modification of OEVs. Finally, we critically summarize the advantages and challenges of organoids and OEVs. In conclusion, we believe that a deeper understanding of organoids and OEVs will provide innovative solutions to complex diseases.
- 6 November 2024
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 22 (1) , 1-21
Open AccessOrganoids and organoid extracellular vesicles-based disease treatment strategies
Organoids are “mini-organs” that self-organize and differentiate from stem cells under in vitro 3D culture conditions, mimicking the spatial structure and function of tissues in vivo. Extracellular vesicles (EVs) are nanoscale phospholipid bilayer vesicles secreted by living cells, rich in bioactive molecules, with excellent biocompatibility and low immunogenicity. Compared to EVs, organoid-derived EVs (OEVs) exhibit higher yield and enhanced biological functions. Organoids possess stem cell characteristics, and OEVs are capable of delivering active substances, making both highly promising for medical applications. In this review, we provide an overview of the fundamental biological principles of organoids and OEVs, and discuss their current applications in disease treatment. We then focus on the differences between OEVs and traditional EVs. Subsequently, we present methods for the engineering modification of OEVs. Finally, we critically summarize the advantages and challenges of organoids and OEVs. In conclusion, we believe that a deeper understanding of organoids and OEVs will provide innovative solutions to complex diseases.
- Open Access
- 1 July 2024
- Published by KEAI Publishing in Bioactive Materials
- Vol. 37, 378-392
MMP13-targeted siRNA-loaded micelles for diagnosis and treatment of posttraumatic osteoarthritis
Posttraumatic osteoarthritis (PTOA) patients are often diagnosed by X-ray imaging at a middle-late stage when drug interventions are less effective. Early PTOA is characterized by overexpressed matrix metalloprotease 13 (MMP13). Herein, we constructed an integrated diagnosis and treatment micelle modified with MMP13 enzyme-detachable, cyanine 5 (Cy5)-containing PEG, black hole quencher-3 (BHQ3), and cRGD ligands and loaded with siRNA silencing MMP13 (siM13), namely ERMs@siM13. ERMs@siM13 could be cleaved by MMP13 in the diseased cartilage tissues to detach the PEG shell, causing cRGD exposure. Accordingly, the ligand exposure promoted micelle uptake by the diseased chondrocytes by binding to cell surface αvβ3 integrin, increasing intracellular siM13 delivery for on-demand MMP13 downregulation. Meanwhile, the Cy5 fluorescence was restored by detaching from the BHQ3-containing micelle, precisely reflecting the diseased cartilage state. In particular, the intensity of Cy5 fluorescence generated by ERMs@siM13 that hinged on the MMP13 levels could reflect the PTOA severity, enabling the physicians to adjust the therapeutic regimen. Finally, in the murine PTOA model, ERMs@siM13 could diagnose the early-stage PTOA, perform timely interventions, and monitor the OA progression level during treatment through a real-time detection of MMP13. Therefore, ERMs@siM13 represents an appealing approach for early-stage PTOA theranostics.
- 1 July 2024
- Published by KEAI Publishing in Bioactive Materials
- Vol. 37, 378-392
Open AccessMMP13-targeted siRNA-loaded micelles for diagnosis and treatment of posttraumatic osteoarthritis
Posttraumatic osteoarthritis (PTOA) patients are often diagnosed by X-ray imaging at a middle-late stage when drug interventions are less effective. Early PTOA is characterized by overexpressed matrix metalloprotease 13 (MMP13). Herein, we constructed an integrated diagnosis and treatment micelle modified with MMP13 enzyme-detachable, cyanine 5 (Cy5)-containing PEG, black hole quencher-3 (BHQ3), and cRGD ligands and loaded with siRNA silencing MMP13 (siM13), namely ERMs@siM13. ERMs@siM13 could be cleaved by MMP13 in the diseased cartilage tissues to detach the PEG shell, causing cRGD exposure. Accordingly, the ligand exposure promoted micelle uptake by the diseased chondrocytes by binding to cell surface αvβ3 integrin, increasing intracellular siM13 delivery for on-demand MMP13 downregulation. Meanwhile, the Cy5 fluorescence was restored by detaching from the BHQ3-containing micelle, precisely reflecting the diseased cartilage state. In particular, the intensity of Cy5 fluorescence generated by ERMs@siM13 that hinged on the MMP13 levels could reflect the PTOA severity, enabling the physicians to adjust the therapeutic regimen. Finally, in the murine PTOA model, ERMs@siM13 could diagnose the early-stage PTOA, perform timely interventions, and monitor the OA progression level during treatment through a real-time detection of MMP13. Therefore, ERMs@siM13 represents an appealing approach for early-stage PTOA theranostics.
- 3 May 2024
- Published by Elsevier in Drug Discovery Today
- Vol. 29 (7) , 104014
Enzyme-responsive liposomes for controlled drug release
- 3 May 2024
- Published by Elsevier in Drug Discovery Today
- Vol. 29 (7) , 104014
Enzyme-responsive liposomes for controlled drug release